From the editor

2020 will undoubtedly go down in history as being the year the world as we know it was crushed by a new coronavirus, thought to have emerged from Wuhan, China, last December. Just 11 months later, around 1.5 million people were recorded as having lost their lives to COVID-19, with millions more left struggling in its wake. Death, lockdown, isolation, furlough, redundancy, PPE, tiers, sanitiser, testing, R numbers and support bubbles are just some of the terms that will forever be synonymous with 2020, depicting a level of bleakness which no-one could have predicted.

However, the darkness also allowed some of the more laudable aspects of humanity to shine brighter, such as the collective recognition and celebration of healthcare workers as superheroes, the banding together of communities to protect their vulnerable, and the linking of academia and industry in a fervent race to find a vaccine, which now seems close to the finish line (see page 7).

Similarly, the healthcare and life sciences sectors quickly had to adapt to a seismic shift in operation necessitated by the pandemic, but this has also had the effect of vastly accelerating progress in certain areas that should ultimately benefit patients, as shown by some of the articles in our Review of the Year. For example, on page 13 John Pinching touches on how the coronavirus has jolted pharma into making digital a force for good, while the team at Wilmington outline how COVID-19 has jump-started the NHS Reset and brought forward changes laid out in the NHS Long Term Plan (p18). Jenny Ousbey also describes the impact of 2020 on the patient experience and how advocacy addressed new challenges (p26).

As 2020 draws to a close, it remains to be seen when the pandemic will end allowing life to begin a return to ‘normal’. However, with several vaccines in late-stage development, as well as a huge spectrum of other treatments designed to boost the chance of surviving COVID-19, it is my hope that this time next year we will find ourselves in an altogether more positive position.

I hope you enjoy the issue!

Selina McKee
editor

PharmaTimes Media Ltd,
Mansard House, Church Road,
Little Bookham, Surrey, KT23 3JG
Tel: +44 (0)20 7240 6999
www.pharmatimes.com Twitter: @PharmaTimes

EDITORIAL
Selina McKee / editor
selina.mckee@pharmatimes.com
Karl Equi / executive director
karl.equi@pharmatimes.com   

SALES & MARKETING
Anna Yeardley / business manager
anna.yeardley@pharmatimes.com

SUBSCRIPTIONS/REPRINTS
Digital and paper copies available free to qualifying readers: www.pharmatimes.com/subscribe
Tel: 01372 414 222
subscriptions@pharmatimes.com
Paper subscriptions available at £90.00 UK and £100.00 overseas per annum.

Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.

Material may not be reproduced in any form without the publisher’s written permission. © Copyright 2020 PharmaTimes Magazine. All rights reserved. PharmaTimes Magazine is published by PharmaTimes Media Ltd, which is registered as a limited company in England; No 09019637.